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Dendritic cells are a promising immunotherapy tool for boosting an individual’s antigen-
specific immune response to cancer. We develop a mathematical model using differen-
tial and delay-differential equations to describe the interactions between dendritic cells,
effector-immune cells, and tumor cells. We account for the trafficking of immune cells
between lymph, blood, and tumor compartments. Our model reflects experimental results
both for dendritic cell trafficking and for immune suppression of tumor growth in mice. In
addition, in silico experiments suggest more effective immunotherapy treatment proto-
cols can be achieved by modifying dose location and schedule. A sensitivity analysis of the
model reveals which patient-specific parameters have the greatest impact on treatment
efficacy.
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1. INTRODUCTION
A promising immunotherapy approach to treating certain can-
cers involves the use of dendritic cells (DCs). DCs are part of
the antigen-specific (adaptive) immune response and function
as antigen-presenting cells. Immature DCs are derived in the
bone marrow and reside in peripheral tissues. Upon encountering
pathogen, DCs begin to mature, and travel to the lymphoid organs
where they stimulate differentiation and maturation of cytotoxic T
lymphocytes (CTLs). Some of these activated CTLs then travel to
the infected tissue to form part of the adaptive immune response,
while others become memory cells that are ready to mount a rapid
response in case of a rechallenge by the pathogen.
Previous studies have established the efficacy of dendritic cell
treatments for tumors in the murine system (DeMatos et al., 1998;
Fields et al., 1998; Lee et al., 2007; Yamaguchi et al., 2007; Shina-
gawa et al., 2008). In these studies, DCs have been shown both
to inhibit the growth of nascent tumors and to provide a mem-
ory response to previously encountered antigen. In the clinic,
researchers have been able to extract immature dendritic cells from
patients, culture them ex vivo, and load them with tumor antigens
to create an individual-based vaccine that can boost a patient’s
response against their own cancerous cells (Pilon-Thomas et al.,
2004; Taquet et al., 2008). The success of clinical trials of DC vac-
cines has resulted in the recent FDA approval of the first cancer
vaccine for prostate cancer (Cheever, 2011). Despite promising
clinical responses in vaccine trials, it remains difficult to predict
which patients will actually respond to these vaccines and why
(Trefzer et al., 2005; Boon et al., 2006). Mathematical models of
DC therapy can provide insight into the mechanisms driving the
kinetics of the immune response that may lead to these disparate
patient responses.
Cell trafficking is an important aspect of the DC-mediated
immune response. DCs must travel from the tumor to the periph-
eral lymph organs via the blood, and activated CTLs must travel
from the lymph organs back to the tumor. Ludewig et al. (2004)
have developed a model describing DC and CTL trafficking in
mice. The model includes activated and memory CTLs to capture
both the immediate and long-term effect of DC injections. The
DC trafficking model of Ludewig et al. was carefully calibrated
using experimental data from murine studies.
In this paper we present an extension and modification of the
model in Ludewig et al. (2004). Our extended model includes a
tumor compartment to allow for analysis of various DC treatments
and their effect on tumor growth, as well as the long-term behavior
of the system. We find relevant model parameters using the data
collected by Lee et al. (2007) describing tumor growth in response
to varying levels of DC injections. We compare model simula-
tions of various DC doses, injection sites, and dose times. We
include a comparison to a prophylactic dosing schedule presented
by Preynat-Seauve et al. (2007).
2. THE MODEL
The compartment model proposed by Ludewig et al. (2004)
includes dendritic cells, activated CTLs, and memory CTLs. Our
extended model includes tumor cells in addition to these immune
cell populations. Adding a tumor compartment requires the deter-
mination of tumor-immune system parameters such as immune
cell trafficking rates to and from the tumor, effector cell deactiva-
tion rates by tumor cells, effector cell death rates, intrinsic tumor
growth rates, and tumor cell kill rates by effector cells. We note that
this compartment model does not account for the geometry of the
system. In particular, it does not explicitly incorporate the distance
between the spleen and the tumor. However, in murine models,
the transit times between compartments are small relative to the
tumor growth time scale, so this simplification is reasonable. In
this section we describe the processes included in the mathematical
model.
2.1. MODEL DEFINITION
Our model consists of three compartments: the spleen, the blood,
and the tumor. Dendritic cells and active effector cells can move
between the blood and spleen compartments, and between the
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blood and tumor compartments. We assume that memory effector
cells can move between the spleen and the blood compartments.
The system is not conservative: all types of cells are cleared through
the blood, immune cells are created in response to the presence of
tumor, and tumor cells grow according to a logistic growth law.
The nine state variables in our model are:
• Dblood, the number of dendritic cells in the blood compartment;
• Dspleen, the number of dendritic cells in the spleen compartment;
• Eablood , the number of activated CTLs in the blood compartment;• Easpleen , the number of activated CTLs in the spleen compart-
ment;
• Emblood , the number of memory CTLs in the blood compartment;• Emspleen , the number of memory CTLs in the spleen compart-
ment;
• Eatumor , the number of activated CTLs in the tumor compart-
ment;
• T, the number of tumor cells;
• Dtumor, the number of dendritic cells in the tumor compart-
ment, the tumor-infiltrating DCs.
We present the system of nine differential equations in group-
ings representing the blood, spleen, and tumor compartments. The
model parameters are described in detail in Table A1 in Appendix.
2.1.1. Blood compartment
The equations describing DC and CTL flow in the blood are
given by:
d
dt
Dblood = −µBDblood + µTBDtumor + vblood (t ) (1)
d
dt
Eablood = µSB
(
Dspleen
)
Easpleen − µBBEablood (2)
d
dt
Emblood = µSB
(
Dspleen
)
Emspleen − µBBEmblood (3)
where, as holds throughout the model, the µ parameters repre-
sent flow rates between compartments. We include the “trapping”
term from Ludewig et al. (2004) which describes the observed phe-
nomenon of activated CTLs being held back in the spleen in the
presence of DCs:
µSB
(
Dspleen
) = µ∗SB + 1µ
1+ DSpleen
θshut
,
1µ = µNormalSB − µ∗SB .
The function vblood(t ) allows us to model injections of DCs into
the blood. For example, two doses of 7× 105 each given on Day 0
and Day 7 could be described by the function:
vblood (t ) =
{
7×105
1/48 , t ∈ (0, 1/48) ∪ (7, 7+ 1/48) ,
0 otherwise.
(4)
2.1.2. Spleen compartment
The differential equations for the spleen compartment describe
interaction, death, and recruitment of DCs and CTL. The equa-
tions include one delay which represents the synaptic connection
time: the contact time required between DCs and effector cells in
the spleen before proliferation can begin. The other interactions
we account for in the system do not involve a required contact
time and thus are modeled without delay. The dynamics of the
populations in the spleen are described by:
d
dt
Dspleen = Max D
(
1− e
(−µBSDblood
Max D
))
− aDDspleen − bDEEaspleenDspleen (5)
d
dt
Easpleen = µBSEEablood − µSB
(
Dspleen
)
Easpleen + baDspleenEmspleen
+ aEaS
(
DConEnaive − Easpleen
)
− ramEaspleen (6)
+ bp
Dspleen (t − τD) Easpleen (t − τD)
θD + Dspleen (t − τD)
d
dt
Emspleen = ramEaspleen −
(
aEm + baDspleen + µSB
(
Dspleen
))
Emspleen
+ µBSEEmblood . (7)
Note that the term in equation (6),
DCon =
{
0 if Dspleen (t ) = 0
1 if Dspleen (t ) > 0.
indicates that we do not allow for new CTLs in the absence of DCs.
Thus, the populations we model only exist due to the presence of
tumor and mature DCs.
The first term in equation (5) reflects our assumption that there
is a maximum rate at which mature DCs can enter the spleen.
This is in agreement with observations that DCs cannot enter the
spleen at an unlimited rate. Based on a range of values for the max-
imum rate we have set MaxD to 400 (cells per hour), reflecting the
parameter fit obtained with the data from Lee et al. (2007) and
Preynat-Seauve et al. (2007). As noted above, in equation (6) the
final term introduces a delay, τ , into the system that reflects the
synaptic connection time. Mathematically, this delay introduces
more complexity into the system, especially regarding the stability
analysis of the equilibria (see Stability Analysis below).
2.1.3. Tumor compartment
The tumor compartment contains activated effector CTLs, DCs,
and tumor cells. The interactions of these populations within the
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tumor are described by:
d
dt
Eatumor = µBTE (T ) Eablood − aEaTEatumor − cEatumorT , (8)
d
dt
T = rT
(
1− T
k
)
−DT . (9)
d
dt
Dtumor = mT
q + T − (µTB + aD)Dtumor + vtumor (t ) (10)
where
µBTE (T ) = µBB (T/ (α + T )) ,
and
D = d
(
Eatumor
T
)l
s +
(
Eatumor
T
)l
.
(11)
The function vtumor(t ) is similar to vblood(t ) in the blood com-
partment, allowing us to inject DCs intratumorally in order to
compare treatment protocols.
Note that in equation (9), tumor growth is fit to a logistic func-
tion as in previous models (de Pillis and Radunskaya, 2003; de
Pillis et al., 2005, 2007, 2009; Cappuccio et al., 2006). The behavior
of this particular model is robust to the choice of growth function,
for example a Gompertz growth law gives similar results. However,
we choose the logistic law since it provides a good fit to the exper-
imental data we are using for model calibration (See Figure 1).
Cytolysis of tumor cells by activated CTLs [equations (9) and (11)]
is a ratio-dependent kill term introduced in de Pillis and Radun-
skaya (2003). Experimental results from Diefenbach et al. (2001)
support ratio-dependent, antigen-specific killing, and the term has
been employed to success in previous models (de Pillis and Radun-
skaya, 2003; de Pillis et al., 2005, 2007, 2009). The importance of
tumor-infiltrating dendritic cells has been demonstrated in several
studies. See, for example, Preynat-Seauve et al. (2007). We allow
DCs in the tumor to increase as a saturation-limited function of
the size of the tumor population.
With this model we simulate a variety of treatment scenarios,
including those investigated in Lee et al. (2007) and Preynat-
Seauve et al. (2007). The model offers insight into how best to
harness the tumor controlling potential of DCs.
3. RESULTS
3.1. PARAMETER DETERMINATION
All unknown parameters were fit to data from Lee et al. (2007)
using a Nelder–Mead least-squares algorithm. The data in Lee
et al. (2007) were collected from C57BL/6 female mice who were
subcutaneously inoculated with 5× 105 B16F10 melanoma cells.
We take this as day 0 for the purpose of fitting unknown parame-
ters so that we may use 5× 105 tumor cells as an initial condition.
Injections of 1× 105, 7× 105, or 21× 105 DCs were given at days
6, 8, and 10, following inoculation with tumor cells. Addition-
ally, a control group was injected with PBS according to the same
schedule (Lee et al., 2007). See Figure 1.
3.2. EQUILIBRIA AND STABILITY ANALYSIS
In order to determine the long-term behavior of the system, we
find the equilibria and determine their stability.
3.2.1. Determination of the equilibria
The system has multiple equilibrium values, determined by set-
ting equations (1–10) to zero. One solution to this system is the
zero, or disease-free, equilibrium. To find the remaining non-zero
equilibria, we first write all the state variables at equilibrium as
functions of T, then search for the values of T that solve all equa-
tions simultaneously. We use asterisks to denote the value of the
variables at equilibrium. Therefore, if there exists a non-zero value
T ∗ that satisfies equation (9), we can use equation (8) to obtain
FIGURE 1 | Fits to data from Lee et al. (2007) and corresponding
residuals. The vertical bars in the graph on the left are the error bars from the
experimental data, and the solid line is the outcome of the model simulation
using the parameters that minimize the distance to the median of those data.
In the graph on the right, the thin vertical bars are the same error bars from
the data, and the solid rectangles show the “residuals,” that is, the distances
between the simulated outcomes and the data. The estimated parameter
values are given inTable A1 in Appendix.
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Ea∗tumor =
{
s(T ∗)l (k − T ∗)
T ∗ − k (1− d/r)
}1/l
. (12)
The value for D∗tumor can also be found in terms of T ∗ using
equation (10):
D∗tumor =
mT ∗
q + T ∗
1
µTB + aD , (13)
where we have replaced DCdeath with its assumed constant
value aD.
Given Ea∗tumor , we can use equation (8) to determine the
equilibrium value of the active effector cells in the blood:
Ea∗blood =
(
aEaT + cT ∗
)
(α + T ∗)
µBBT ∗
Ea∗tumor . (14)
We use equations (13) and (1) to obtain D∗blood in terms of T
∗:
D∗blood =
µTBD∗tumor
µB
= µTB
µB
(
1
µTB + aD
)
mT ∗
q + T ∗ .
Equation (3) gives an expression for Em∗blood in terms of E
m∗
spleen ,
Em∗blood =
µSB
(
Dspleen
)
µBB
Em∗spleen .
Turning to the spleen compartment, we have:
Ea∗spleen =
µBB
µSB
(
Dspleen
)Ea∗blood .
Using (14) and (12), this gives Ea∗spleen in terms of T
∗. According
to equation (5), knowing D∗blood allows determination of D
∗
spleen .
Using equation (6) results in the following quadratic equation for
D∗spleen :
0 = −θshut
(
µ∗SB +1µ
)Din {θshutµ∗SBaD +1µθshut aD
+θshut bDEµBBEa∗Blood − µ∗SBDin
}
D∗spleen{
µ∗SBaD + bDEEa∗BloodµBB
} (
D∗spleen
)2
,
(15)
where
Din = Max D
{
1− exp
(−µBSDblood
Max D
)}
.
Solving this quadratic equation yields two different, relevant
equilibrium values for D∗spleen . From equation (7) we get a value
for Em∗spleen for each value of D
∗
spleen :
Em∗spleen =
ramEa∗spleen
aEm + baD∗spleen + µSB
(
D∗spleen
)
{1− µBSE/µBB}
.
Finally, from equation (6), the roots of the following function,
expressible in terms of one variable, T ∗, yield equilibrium values
for T ∗.
Z
(
T ∗
) = µBSEEa∗blood − µSB (D∗spleen) Ea∗spleen + baD∗spleenEm∗spleen
+ aEaS
(
DConEnaive − Ea∗spleen
)
− ramEa∗spleen
+ bp
D∗spleenE
a∗
spleen
θD + D∗spleen
.
(16)
From equation (12), we see that as long as the values of T ∗, and
thus the roots of (16), lie between k(1− d/r) and k, a non-zero
equilibrium state exists. Recall that d, r, and k are the parame-
ters that represent the tumor cell kill, intrinsic growth rates, and
tumor carrying capacity, respectively. The functionZ (T ) is plotted
in Figure 2 for the parameter set given in Table A1 in Appendix.
3.2.2. Stability of the equilibrium points
A stability analysis of the system of delay equations (1–10) can be
carried out by analyzing the linear approximation to the system at
an equilibrium point. Since the termD(T , Eatumor ), given in equa-
tion (11), is not differentiable at (0, 0), the system of DEs is not
differentiable and, hence, has no linear approximation at the ori-
gin. Although we cannot use the linearization in this case, we do
have numerical simulations that indicate that the tumor free equi-
librium is initially unstable, but gains stability as the value of d,
the immune strength parameter, is increased (see Figure 9). There
is ongoing investigation of the analytical nature of the stability of
the disease-free equilibrium.
At other equilibria, the linearization is given by two matri-
ces of partial derivatives, J 0 and Jτ . To simplify the notation, we
denote the nine state variables as x1 through x9 and the delayed
state variables as zi(t )= xi(t − τ ). If the rate of change of xi is
denoted by:
dxi
dt
= Fi(x1, . . . x9, z1, . . . z9)
then the entries of the Jacobians are:
J0
(
i, j
) = ∂Fi
∂xj
, Jτ (i, j) = ∂Fi
∂zj
The formulas for the entries of J 0 and Jτ are given in
Appendix B.
The eigenvalues of the derivative matrices at an equilibrium,
E can be determined by finding the roots of the characteristic
polynomial P(λ, τ ), where P is defined by:
P (λ, τ) = det (J0(E)+ e−λτ Jτ (E)− λI)
For most systems of delay-differential equations, determining
the roots of the characteristic polynomial is a non-trivial process.
Given our equations and particular parameter set, there exist two
positive equilibrium values ofT ∗ (see Figure 2). However,only one
of these values result in positive (biologically relevant) equilibrium
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FIGURE 2 | Graph of the function Z given in equation (16). The two zeros, marked by dots, correspond to equilibrium values of T. The function becomes
complex as T →109. The two curves correspond to the two roots of equation (15).
values for all other state variables (see Appendix B). For this bio-
logically relevant equilibrium, in the non-delay (or τ = 0) case,
all eigenvalues of the derivative matrix J 0 have negative real part
(see Appendix B). Because this is equivalent to the non-delay case,
we know that when τ = 0, the non-trivial equilibrium is stable.
It is possible for an equilibrium to change stability as the delay
increases from zero. In our case numerical simulations suggest
that this equilibrium maintains its stability even for large values of
the delay, τ (see Figure 3).
3.3. CALIBRATION AND VALIDATION OF DC EFFECT ON TUMOR
GROWTH
In this section we discuss the validation of the model. Start-
ing with parameter values estimated in Ludewig et al. (2004),
we then calibrate DC and CTL dynamics against the data pro-
vided by the experiments in Lee et al. (2007). In the discussion
section we present a number of numerical experiments in which
we explore the difference between intravenous and intratumoral
DC injections, as well as modifications of the dose timings with
hypothetically improved treatment schedules.
Experiments carried out in Lee et al. (2007) give tumor growth
data, both in the presence and absence of DC treatment. We fit our
intrinsic tumor growth parameters to the PBS melanoma growth
data provided by Lee et al. (2007). Since specific trafficking para-
meters to and from the tumor have not been measured, we used the
tumor growth data provided to infer the parameter values needed
for the tumor compartment DC and CTL dynamics.
In Lee et al. (2007), groups of three 6–8-week-old female
C57BL/6 mice were challenged with 5× 105 B16F10 melanoma
cells on day 1, then treated with DC injections starting on days
6, 8, and 10. In separate experiments, DC doses of size 1× 105,
7× 105, and 21× 105 were administered. Lee et al. point out that
the largest DC dose is most effective at slowing tumor growth. In
fact, according to Lee et al., the largest dose regimen of 21× 105
DCs injected three times provided up to 41% tumor growth sup-
pression as compared to the control mice. Survival time for these
mice was increased by approximately 60%. We note that, even with
the most aggressive DC treatment attempted, tumor growth was
not completely suppressed.
In Figure 4, left panel, we see the change in tumor volume over
20 days, and compare tumor growth with no DC treatment to
growth with varying levels of DC treatment. Simulated DC doses
are 1× 105, 7× 105, and 21× 105, reflecting the laboratory exper-
iments of Lee et al. (2007). After a tumor challenge of 5× 105
B16F10 melanoma cells on day 1, DC injections of the specified
doses were then given intratumorally on days 6, 8, and 10. The
simulation results fall well within the data ranges provided by Lee
et al. (2007).
4. DISCUSSION
In Section 3 we validated and calibrated the model, and analyzed
the long-term behavior of the system. We are now in a position
to explore hypothetical treatment variations. In this section, we
discuss the effects of varying treatment protocols, and possible
implications for patients. In Section 4.1, we compare intratumoral
DC injections to hypothetical intravenous DC injections. We will
see that when injecting the smallest dose of DCs, hypothetical
intravenous DC injections are more effective at suppressing tumor
growth than are DCs injected directly into the tumor. However,
intratumoral injections are more effective than intravenous injec-
tions when the highest DC dose is used. In Section 4.2, we explore
the effect of modifying dose timings. We will see that fractionated
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FIGURE 3 |This figure presents a sampling of several simulations
for various values of the delay, τ and several different initial
conditions (IC). The solid black line (topmost curve) shows a
simulation with initial value 9.82×108 with τ =16. The other curves
(from top to bottom) are the results of simulations using (τ , IC) pairs:
(2, 9.817×108), (0.5, 9.835×108), (0.1, 9.811×108), (8, 9.8×108). For
each value of τ , we simulated several initial conditions ranging
between 9.80×108 and 9.82×108 (other simulations not shown)
and, in each case, the cell populations approached the same
equilibrium value.
FIGURE 4 | Fractionated dosing comparison. Intratumoral injections. Compare original DC dosing schedule (left panel) to hypothetical fractionated dosing
schedule (right panel).
doses that are administered intravenously delay tumor growth sig-
nificantly. We will see that earlier treatment initiation also helps
suppress tumor growth, but more so with intratumoral injections.
Up to this point,we have found ways to slow tumor growth by vary-
ing dose timing and location, but have not been able to completely
eliminate a tumor. In Section 4.3, we explore the effects of prophy-
lactic DC dosing. We find that prophylactic DC dosing actually
allows us to eliminate a tumor under the right circumstances.
We will see that as long as the CTL immune response is suffi-
ciently strong, as reflected by the immune strength parameter d, a
tumor that is introduced after DCs are injected can be completely
suppressed.
4.1. INTRATUMORAL VERSUS INTRAVENOUS TREATMENT
We first compare the effect of treatment at two different injec-
tion sites. In the work of Preynat-Seauve et al. (2007) DC
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trafficking resulting from different injection sites was compared.
They observed that there is a “trapping effect” within the tumor:
DCs injected intratumorally do not reach the lymph nodes in
significant numbers, indicating that the DCs are “trapped” for a
time within the tumor. Note that this trapping is a different phe-
nomenon from the one described in Section 2.1 which referred
to activated CTLs being held back in the spleen in the presence
of DCs. Preynat-Seauve et al. observed that subcutaneous DC
injections resulted in DCs getting to the lymph nodes in greater
numbers. In our numerical experiments,we compare intratumoral
DC injections (as was done in the Lee et al. (2007) experiments)
to intravenous DC injections. We note that intravenous injec-
tions and subcutaneous injections are not equivalent, but both
approaches do avoid the trapping effect of intratumoral injections.
In Figure 5, left panel, we see the effects on melanoma growth of
hypothetical intravenous DC injections over a 20 day period. Sim-
ulated DC doses of size 1× 105, 7× 105, and 21× 105 are admin-
istered. The no-treatment tumor growth case is also included for
comparison. After a tumor challenge of 5× 105 B16F10 melanoma
cells on day 1, DC injections of the specified doses were then given
on days 6, 8, and 10.
It is interesting to note that in these simulations, all three intra-
venous dose responses appear to be nearly equally effective. There
is little difference between low-dose and high-dose intravenous
injection outcomes, while there is a significant difference between
low-dose and high-dose intratumoral injection outcomes. In addi-
tion, when we compare Figure 5, left panel, to Figure 4, left panel,
we see that all three intravenous doses control the tumor growth
about as effectively as the mid-sized 7× 105 intratumoral dose
(that is, the intravenous doses are all more effective than the low-
est tumor dose, but less effective than the highest tumor dose). The
reason for this result can be explained mathematically by the pres-
ence of theMaxD term in the model, equation (5). This term limits
the rate at which DCs can enter the spleen, which in turn limits how
saturated with DCs the spleen can get. Consequently, this limited
inflow rate works against any treatment that attempts to send DCs
into the spleen too quickly. MaxD term limits DC inflow into the
spleen, the total number of DCs in the spleen over MaxD limit. In
the case of the low-dose injections, the DCs injected intravenously
all enter the spleen, since their entry rate is not limited by MaxD,
while the low intratumoral dose suffers some DC loss from the
tumor. This can explain why the low-dose intravenous injection is
more effective than the low-dose intratumoral injection. However,
in the high-dose injection cases, the number of DCs entering the
spleen from the high-dose intravenous treatment is being limited
by the MaxD inflow ceiling. On the other hand, the high-dose
intratumorally injected DCs enter the spleen more slowly, so even
though there is still loss from the tumor, a greater total number of
DCs remain in the spleen longer than in the case of the high-dose
intravenous injection.
As discussed earlier, the model does not explicitly account for
the distance between the spleen and the tumor. If we were to extend
the model so that it could apply to human subjects, these distances
could vary significantly between individuals. One possible model
extension would incorporate the effect of transit times with a par-
tial differential equation that includes a distance L along which
cells diffuse and convect.
4.2. MODIFIED DOSING
In this section we explore the hypothetical effect of modifying
dose timings. We first investigate the effect of administering the
same total medication over a 20 day time frame, but with more
frequent injections; that is, a fractionated dosing schedule. The
original dosing schedule starts on day 6, and administers a total of
three doses spaced apart by 2 days. The hypothetical fractionated
dosing schedule we explore also starts on day 6, but administers
doses twice a day at 1/4 the original dose.
In Figure 4, we compare simulated melanoma growth in
response to DCs administered according to the original proto-
col with a hypothetical fractionated dosing schedule. Injections
are given intratumorally. The no-treatment tumor growth case is
also included for comparison. After a tumor challenge of 5× 105
B16F10 melanoma cells on day 1, the original dosing calls for
DC injections of 1× 105, 7× 105, and 21× 105 administered
every other day on days 6, 8, 10. The hypothetical fraction-
ated schedule administers doses of 0.25× 105, 1.75× 105, and
FIGURE 5 | Fractionated dosing comparison. Intravenous injections.
Compare original DC dosing schedule (left panel) to hypothetical fractionated
dosing schedule (right panel). 5× 105 B16F10 melanoma cells on day 1, the
original dosing calls for DC injections of 7×105, and 21×105 administered
every other day on days 6, 8, 10 (pictured in graphs 0.25×105, 1.75×105, and
5.25×105 twice a day on days 6, 7, 8, 9, 10, 11.
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FIGURE 6 | Early treatment initiation: start day 3. Original dosing (top row)
and fractionated dosing (bottom row) compared. 5×105 B16F10 melanoma
cells on day 1, DC injections of 7×105, and 21×105 are administered both
intratumorally and intravenously 0.25×105, 1.75×105, and 5.25×105 twice a
day on days 3, 4, 5, 6, 7, 8. Treatment is given both intratumorally (left column)
and intravenously (right column).
FIGURE 7 | Compare original to earlier treatment initiation, intravenous, non-fractionated dosing. Treatment start day 6 (left) compared to start day 3
(right).
5.25× 105 twice a day on days 6, 7, 8, 9, 10, 11. The total DC
treatment administered is the same in the original and fraction-
ated dosing scenarios. It is clear that the fractionated sched-
ule does not improve outcomes in the case of intratumoral
injections.
In Figure 5, we again compare the original DC dosing sched-
ule to a fractionated dosing schedule, but we now use intravenous
injections. As before, after a tumor challenge of 5× 105 B16F10
melanoma cells on day 1, the original treatment schedule calls for
DCs of doses 1× 105, 7× 105, and 21× 105 given every other day
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on days 6, 8, 10. The hypothetical fractionated schedule admin-
isters doses of 0.25× 105, 1.75× 105, and 5.25× 105 twice a day
on days 6, 7, 8, 9, 10, 11. The total amount of DC administered
is the same in both scenarios. The simulations highlight that
although the fractionated schedule does not improve outcomes
in the case of intratumoral injections, greater tumor control is
observed when the fractionated treatment is administered intra-
venously. Although tumor growth is slowed with the intravenously
dosed fractionated schedule, it is not completely controlled, and
the tumor still eventually grows.
We next investigate the effect of starting the DC treatment
regimen earlier than day 6. In this case, we compare fraction-
ated DC doses both intratumorally and intravenously, but with
treatment initiated on day 3 instead of day 6. The experimen-
tal outcomes are pictured in Figure 6. After a tumor challenge of
5× 105 B16F10 melanoma cells on day 1, DC injections of 1× 105,
7× 105, and 21× 105 are administered both intratumorally and
intravenously on days 3, 5, 7 (pictured in graphs in the top row
of Figure 6). The hypothetical fractionated schedule (pictured
in the second row of Figure 6) administers doses of 0.25× 105,
1.75× 105, and 5.25× 105 twice a day on days 3, 4, 5, 6, 7, 8. The
total DC treatment administered is the same in all scenarios. We
see that in both the intratumoral and intravenous dosing cases,
tumor growth is slowed when treatment starts on day 3. How-
ever, as before, fractionating the intratumoral doses does not have
much effect (bottom left panel), but does slow tumor growth even
further when administered intravenously (bottom right panel).
Interestingly, the earlier start day has less effect when administered
intravenously than it does when administered intratumorally, as
can be seen in Figure 7. Here we compare non-fractionated intra-
venous dosing starting on day 6 (left panel) and on day 3 (right
panel). Initial values and doses follow the original schedule. The
result with fractionated dosing is similar, but is not pictured. We
see that there is some improvement with the early start intravenous
dosing, but the improvement is not as large as the improvement
seen with the intratumoral doses started on day 3, as pictured in
the left column of Figure 6.
4.3. PROPHYLACTIC VACCINATION
So far, we have been investigating the responses of our system
to DC treatment after a tumor challenge. However, DC treat-
ments have also been considered to have potential as prophylactic
FIGURE 8 | Partially Ranked Correlation Coefficients (PRCC) for two outcomes: final tumor size, and final CTL levels. Parameters with negative PRCCs
relative to final tumor levels are negatively correlated with tumor growth. Increasing such parameters would be beneficial to the patient. An increase in
parameters with positive PRCCs relative to final tumor levels, or with negative PRCCs relative to final CTL levels could be harmful to the patient.
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vaccines. For example, the work of Preynat-Seauve et al. (2007)
details a variety of studies on tumor growth in mice inoculated
with DC treatments prior to a tumor challenge. Although our
model has not been constructed specifically to investigate preven-
tative vaccination, we did see some interesting results when sim-
ulating such treatment. In one of the experiments from Preynat-
Seauve et al. (2007), DC cells from tumors were cultivated and
injected into B6C3F1 mice. Vaccination was performed twice, once
weekly, with 105 tumor-infiltrating dendritic cells. The authors
state that this number corresponds to the total number of CD11c+
cells recovered from a single 1 cm-diameter tumor. Two weeks after
the last injection, mice were challenged with 2× 105 melanoma
cells (either K1735 or B16F10). According to the study, vaccinated
mice were protected for 22 days, whereas naive mice succumbed
to the tumor challenge.
Using the same parameter values we determined through fit-
ting to the data in Lee et al. (2007), a simulation of pre-vaccination
with mature DCs showed no particular benefit. In order to deter-
mine the sensitivity of the system to a change in parameters we
used the Latin Hypercube sampling method described in Blower
and Dowlatabadi (1994) to compare simulations with 50,000 ran-
domly generated parameter sets. The effect of a change in parame-
ter values on tumor size and CTL levels after 45 days was quantified
by calculating the partially ranked correlation coefficients for each
parameter that showed a monotonic relationship to the outcomes.
The results are shown in Figure 8.
The sensitivity analysis indicates that tumor levels are sensitive
to the parameters d, m, and µTB. Since d, the fractional tumor
kill rate by CTLs, has the potential to be manipulated through
treatments (c.f.Chakraborty et al., 2003), we suggest that this para-
meter might play an important role in the vaccine’s effectiveness.
In subsequent simulations, when d was increased we observed a
protective effect of prophylactic vaccination with DCs. In Figure 9
we see tumor growth both without and with DC vaccination with
FIGURE 9 | Prophylactic vaccination and the effect of varying immune
strength parameter d. Top panel, no vaccine. Bottom panel, vaccinate
with DC treatments, days 0 and 7, 1×105 DCs per dose. Tumor challenge
on day 21, with 2×105 tumor cells. Dosing follows Preynat-Seauve et al.
(2007) experiment. With d =1, tumor is controlled as a result of
vaccination.
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d = 0.35, 0.85, 1.0, and 1.25. The results for d = 1 are what interest
us. When d = 1.25, the immune system is sufficiently effective to
suppress tumor growth without treatment intervention. In con-
trast, when d = 1 or less, then without DC vaccination, the tumor
grows rapidly. However, if the tumor challenge has been preceded
by two doses of a DC vaccine, then even when d = 1, tumor growth
is suppressed. We also extended the simulations out 165 days after
the tumor challenge (not pictured). For d ≥ 1, the tumor shrank
to zero after vaccination and did not regrow. Numerically, this
indicates that the zero tumor equilibrium is stable.
5. FUTURE DIRECTIONS
In this paper, we presented a model of Dendritic Cell trafficking
and interaction with a tumor cell population. With this model,
we achieved simulation outcomes that quantitatively match pub-
lished data from studies on mice (Lee et al., 2007) that first were
challenged with tumor and subsequently treated with DC therapy.
We then used the model to test a wider variety of hypothetical
treatment scenarios. In addition, we examined the effects of
prophylactic vaccination with DCs. The simulation results from
the prophylactic vaccination scenarios that were discussed in the
previous section are preliminary, but do show qualitative agree-
ment with a different set of data from published laboratory
experiments on mice (Preynat-Seauve et al., 2007).
In future work, we will investigate how to scale this model to
reflect tumor growth and DC trafficking in humans. This will
involve a careful examination of the effect of distances between
the tumor site and the lymph organs. In addition, we will fur-
ther investigate the effects of prophylactic vaccination. Our goal is
to determine which parameters and model terms need tuning to
achieve quantitative as well as qualitative outcomes that reflect the
laboratory data.
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APPENDIX
A. PARAMETER VALUES
The parameters are described in Table A1. Refer to Ludewig et al. (2004) for justification and confidence intervals for the parameters
measured in that study.
Table A1 | Parameter values.
Parameter name Description Value Units Reference
aD Natural death rate of DCs 0.2310 1/day Ludewig et al. (2004)
aEaS Death rate of activated CTLs in spleen 0.1199 1/day Ludewig et al. (2004)
aEaT Death rate of activated CTLs in tumor compartment 0.462 1/day de Pillis et al. (2006)
aEm Natural death rate of memory CTLs 0.01 1/day Ludewig et al. (2004)
α Component of µBTE 1 Cell
ba = b˜a/Qspleen Per cell activation rate of memory CTLs by DCs 0.01 1/(cell ·day)
b˜a Activation rate of memory CTL concentration by DCs 1×10−3 ml/(cell ·day) Ludewig et al. (2004)
bDE = b˜DE /Qspleen Per cell elimination rate of DCs by activated CTLs 1.3×10−6 1/cell ·day
b˜DE Elimination rate of DCs by activated CTLs (per concentration) 1.3×10−7 ml/cell/day Ludewig et al. (2004)
bp Maximal expansion factor of activated CTL 85 1/day Ludewig et al. (2004)
c Rate at which activated CTLs are inactivated by tumor cells 9.42×10−12 1/(cell ·day) de Pillis et al. (2006)
d Maximum fractional tumor kill by CTLs 0.35 1/day Fit to Lee et al. (2007)
Enaive Number of naive CTL cells contributing to primary clonal
expansion
370 Cells Ludewig et al. (2004)
k Carrying capacity of tumor 1.0×109 Cells Fit to Lee et al. (2007)
l Immune strength scaling exponent 23 Unitless Ad hoc value
m Maximum recruitment rate of DCs to tumor site 2.4388×104 Cells/day Fit to Lee et al. (2007)
µB Rate of DC emigration from blood. Note: µB=µBS+
24(µBLi+µBLu+µBO), the sum of DC outflow to the spleen,
liver, lung, and other parts of the body
27.072 1/day Ludewig et al. (2004)
µBB = µ˜BB − µBL Scaled and shifted elimination (clearance and extravasation)
rate of CTL from blood
5.7 1/day
µ˜BB Total elimination rate of CTL from blood 5.8 1/day Ludewig et al. (2004)
µBL Transfer rate of DCs from the blood to the liver 0.1 1/day Ludewig et al. (2004)
µBS Transfer rate of DCs from blood to spleen 2.832 1/day Ludewig et al. (2004)
µBSE = µ˜BSE Qspleen/Qblood Scaled transfer rate of activated CTLs from blood to spleen 7.33×10−4 1/day
µ˜BSE Transfer rate of activated CTLs from blood to spleen 0.022 1/day Ludewig et al. (2004)
µBTE = µBB Tα+T T-dependent rate at which effector cells enter the tumor
compartment from the blood
Calculated 1/day
µLB Transfer rate of DCs from the liver to the blood 0.51 1/day Ludewig et al. (2004)
µNormalSB Normal DC transfer rate from spleen to blood 0.512 1/day Ludewig et al. (2004)
µ∗SB DC reduced transfer rate from spleen to blood 0.012 1/day Ludewig et al. (2004)
µTB Rate of transfer of DC from tumor to blood 0.0011 1/day Ad hoc value
(Continued)
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Table A1 | Continued
Parameter name Description Value Units Reference
q Value of T necessary for half-maximal DC recruitment 100 Cells Fit to Lee et al. (2007)
Qblood Murine blood volume 3 ml Ludewig et al. (2004)
Qliver Murine liver volume 0.5 ml Ludewig et al. (2004)
Qspleen Murine spleen volume 0.1 ml Ludewig et al. (2004)
r Tumor growth rate 0.3954 1/day Fit to Lee et al. (2007)
ram Reversion rate of activated CTL to memory CTL 0.01 1/day Ludewig et al. (2004)
s Value of (Eatumor /T )
l necessary for half-maximal activated
CTL toxicity
1.4 Unitless Fit to Lee et al. (2007)
τD Duration of preprogramed CTL divisions 0.5 Days Fit to Lee et al. (2007)
θD = θ˜DQspleen Scaled threshold in DC density in the spleen for
half-maximal proliferation rate of CTL
212 Cell
θ˜D Threshold in DC density in the spleen for half-maximal
proliferation rate of CTL
2.12×103 Cell/ml Ludewig et al. (2004)
θshut = θ˜shut Qspleen Scaled threshold in DC density in the spleen for
half-maximal transfer rate from spleen to blood
1.3 Cells Ludewig et al. (2004)
θ˜shut Threshold in DC density in the spleen for half-maximal
transfer rate from spleen to blood
13 Cells/ml Ludewig et al. (2004)
www.frontiersin.org March 2013 | Volume 3 | Article 56 | 13
DePillis et al. A model of dendritic cell therapy for melanoma
B. STABILITY ANALYSIS: JACOBIANS
Recall that J 0 is the Jacobian for the non-delayed system, in
other words, its entries are given by J 0(i, j)= dFi/dxj, and
Jτ (i, j)= dFi/dzj is the Jacobian for the delayed system. For
computational ease, we rename the state variables as follows:
Dblood = x1, Dspleen = x2, Eablood = x3,
Easpleen = x4, Emblood = x5, Emspleen = x6,
Eatumor = x7, T = x8, Dtumor = x9.
There are only two delayed variables:
Dspleen (t − τ) = z2, Easpleen (t − τ) = z4.
We perform the stability analysis without any treatment, i.e.,
vblood= vtumor= 0. The non-zero elements of J 0 are calculated
to be:
J0 (1, 1) = −µB
J0 (1, 9) = µTB
J0 (2, 1) = −µBSe
(−µBSx1
Max D
)
J0 (2, 2) = −aD − bDEx4
J0 (2, 4) = −bDEx2
J0 (3, 2) = −1µ
θshut
x4
(1+ x2/θshut )2
J0 (3, 3) = −µBB ,
J0 (3, 4) = µSB
(
Dspleen
)
,
J0 (4, 2) = −1µ
θshut
x4
(1+ x2/θshut )2
+ bax6
J0 (4, 3) = µBSE
J0 (4, 4) = −µSB
(
Dspleen
)− aEa s − ram
J0 (4, 6) = bax2
J0 (5, 2) = −1µ
θshut
x6
(1+ x2/θshut )2
J0 (5, 5) = −µBB , J0 (5, 6) = µSB
(
Dspleen
)
J0 (6, 2) = −
(
ba − 1µ
θshut
1
(1+ x2/θshut )2
)
x6
J0 (6, 4) = ram
J0 (6, 5) = µBSE
J0 (6, 6) = −
(
aEm + bax2 + µSB
(
Dspleen
))
J0 (7, 3) = µBTE (T )
J0 (7, 7) = −aEaT − cx8
J0 (7, 8) = µBBα
(α + x8)2
x3 − cx7
J0 (8, 7) = dsl(x7/x8)
l−1{
s + (x7/x8)l
}2
J0 (8, 8) = r − 2rx8
k
− dsl(x7/x8)
l{
s + (x7/x8)l
}2 + d(x7/x8)ls + (x7/x8)l
J0 (9, 8) = mq(
q + x8
)2
J0 (9, 9) = − (µTB + aD)
where µBTE (T ) = µBB Tα+T , and µSB
(
Dspleen
) = µ∗SB +
1µ
1+Dspleen/θshut .
There are only two non-zero elements of Jτ :
Jτ (5, 4) = bp z5θD
(θD + z4)2
, Jτ (5, 5) = bpx4
θD + z4 .
As referenced in the text, there are two positive tumor equilib-
rium values, T ∗:
T ∗1 ≈ 9.72× 108; T ∗2 ≈ 9.81× 108.
However, the first one results in a non-biologically relevant
equilibria as it corresponds to a negative equilibrium value for x2,
x4,x5. For the non-delay case (i.e., τ = 0,) there are no Jτ elements.
Thus we consider the eigenvalues of J 0. At the positive (biologi-
cally relevant) equilibria, the eigenvalues of J 0, as computed via
MatLab to four decimal places, are
Ee = [−27.0720,−11.1021,−0.6765,−0.4719,−0.3918,
− 0.3092,−0.2321,−5.7000,−5.7000].
Each eigenvalue clearly satisfies R(λ)< 0, indicating that, in
the non-delay case, the biologically relevant equilibrium is stable.
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